Zydus gets DCGI nod for drug to treat anaemia associated with chronic kidney disease


PTI, Mar 7, 2022, 12:39 PM IST

Image Source: Twitter / @ZydusUniverse

New Delhi: Zydus Lifesciences on Monday said it has received approval from the Drug Controller General of India (DCGI) for Oxemia (Desidustat), a first-of-its-kind oral treatment for anemia associated with chronic kidney disease (CKD).

The drug firm, formerly known as Cadila Healthcare, said it has received approval for its new drug application (NDA) product.

The clinical development programme of Desidustat was one of the largest trials of its kind in India for Anemia in CKD patients, conducted in over 1,200 subjects, it added.

”Our life-changing discoveries are guided by the need to help patients lead a better life and empower them with therapies that enable them to live healthier and more fulfilled lives.

”There was a potential for an oral, safer alternative to currently available injectable erythropoietin-stimulating agents (ESAs),” Zydus Lifesciences Chairman Pankaj R Patel noted.

After more than a decade of research and development into the science of HIF-PH inhibitors, results have demonstrated that Oxemia (Desidustat) addresses this unmet need and additionally reduces hepcidin, inflammation and enables better iron mobilization, he added.

”This advancement offers ease of convenience for the patient and will also reduce the disease burden by providing treatment at an affordable cost, thereby improving the quality of life for patients suffering from chronic kidney disease,” Patel stated.

CKD is a serious progressive medical condition characterized by a gradual loss of kidney function, usually accompanied by other co-morbidities, including anemia, cardiovascular diseases (hypertension, heart failure, and stroke), and diabetes mellitus, eventually leading to kidney failure.

As per industry estimates, 115.1 million people in India, 132 million in China, 38 million in the United States, 21 million in Japan, and 41 million people in Western Europe are estimated to be living with CKD.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Ambedkar row: Congress to hold nationwide protest against Amit Shah’s remarks

Special trains announced from Bengaluru for Christmas and Kumbh Mela

H D Kumaraswamy announces Rs 15,000 crore revival plan for Bhadravati Visvesvaraya Iron & Steel Factory

Allu Arjun didn’t leave theatre despite being told about woman’s death: Hyderabad police

Kannada Sahitya Sammelana: Food distribution creates stir

Rohit gets hit in nets, practice pitches on slower side

India & Kuwait elevate ties to strategic level; ink defence pact after PM Modi meets top Kuwaiti leaders

Related Articles More

RBI: After another status quo year, all eyes on a growth-propping rate cut with new Guv at helm

Front-running case: Sebi bans 9 entities from market , impounds illegal gains of over Rs 21 crore

Global trends, FIIs’ move to dictate trends in markets in holiday-shortened week: Analysts

GST Council postpones decision to cut tax on insurance, rate panel defers report submission

GST Council meet to decide on lower taxes on insurance policies, ATF inclusion

MUST WATCH

Tulunadu Daivaradane

Feeding Birds with Creative Paddy Art!

Areca Nut

HOTEL SRI DURGA BHAVANA

Harish Poonja


Latest Additions

Ambedkar row: Congress to hold nationwide protest against Amit Shah’s remarks

Special trains announced from Bengaluru for Christmas and Kumbh Mela

H D Kumaraswamy announces Rs 15,000 crore revival plan for Bhadravati Visvesvaraya Iron & Steel Factory

Allu Arjun didn’t leave theatre despite being told about woman’s death: Hyderabad police

Kannada Sahitya Sammelana: Food distribution creates stir

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.